Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 11:39:58 GMT 2023
by
admin
on
Sat Dec 16 11:39:58 GMT 2023
|
Protein Type | ENZYME |
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
T8635M4C7O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 862.1520
Created by
admin on Sat Dec 16 11:39:59 GMT 2023 , Edited by admin on Sat Dec 16 11:39:59 GMT 2023
|
||
|
LOINC |
1690-7
Created by
admin on Sat Dec 16 11:39:59 GMT 2023 , Edited by admin on Sat Dec 16 11:39:59 GMT 2023
|
||
|
LOINC |
1689-9
Created by
admin on Sat Dec 16 11:39:59 GMT 2023 , Edited by admin on Sat Dec 16 11:39:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P21589
Created by
admin on Sat Dec 16 11:39:59 GMT 2023 , Edited by admin on Sat Dec 16 11:39:59 GMT 2023
|
PRIMARY | |||
|
9027-73-0
Created by
admin on Sat Dec 16 11:39:59 GMT 2023 , Edited by admin on Sat Dec 16 11:39:59 GMT 2023
|
PRIMARY | |||
|
T8635M4C7O
Created by
admin on Sat Dec 16 11:39:59 GMT 2023 , Edited by admin on Sat Dec 16 11:39:59 GMT 2023
|
PRIMARY | |||
|
P21589
Created by
admin on Sat Dec 16 11:39:59 GMT 2023 , Edited by admin on Sat Dec 16 11:39:59 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_25 | 1_31 |
1_327 | 1_332 |
1_339 | 1_361 |
1_450 | 1_453 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_27 |
N | 1_285 |
N | 1_307 |
N | 1_377 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Targets and binds to CD73, leading to clustering and internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes.
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
In vitro and in vivo pharmacology studies show INCA00186 to be a potent binder and inhibitor
of CD73 function
IN-VITRO, IN-VIVO
|
||
|
PARENT->INNOVATOR | |||
|
INHIBITOR -> TARGET |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|